Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

Nilofer S. Azad, Edwin M. Posadas, Virginia E. Kwitkowski, Seth M. Steinberg, Lokesh Jain, Christina M. Annunziata, Lori Minasian, Gisele Sarosy, Herbert L. Kotz, Ahalya Premkumar, Liang Cao, Deborah McNally, Catherine Chow, Helen X. Chen, John J. Wright, William D. Figg, Elise C. Kohn

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity'. Together they form a unique fingerprint.

Medicine & Life Sciences